Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Asedebart

Phase 2

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

AdrenalNot yet recruiting

AdrenalPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q3 2031

Phase 2Not yet recruiting

Adrenal

NCT07859293

Clinical

Trials by Indication[1]

Adrenal1 trial

Interventional, Open-label, Extension Trial of Asedebart (Lu AG13909) in Participants With Congenital Adrenal Hyperplasia

Not yet recruiting· Lundbeck logo

Lundbeck·Phase 2·NCT07859293·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Asedebart. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Asedebart. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Lundbeck company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Lundbeck

Related News